Neratinib is another irreversible pan-HER inhibitor targeting EGFR, HER2, and HER4, currently approved for the treatment of HER2-positive breast cancer and currently under clinical development for other tumours, including CRC [137]. This evidence concerns the gene ERBB2 and neoplasm.